Dipeptidyl Peptidase IV inhibitory activity of Mangifera indica

The insulinotropic hormone, glucagon-like peptide 1 (GLP-1), which has been proposed as a new treatment for type 2 diabetes, is metabolized extremely by Dipeptidyl peptidase IV (DPP-IV). Inhibitors of DPP IV enhance the level of GLP-1, which have improved glucose tolerance and increased insulin secretion. To understand the therapeutic activity of Mangifera indica for the treatment of non-insulin dependent diabetes mellitus (NIDDM). The methanolic extract of Mangifera indica leaves were tested in-vitro for DPPIV inhibitory activity. The extract showed potent activity with an IC 50 value of 182.7μg/ml. Diprotin-A was used as reference standard. The results confirm the inhibitory effect of M. indica on DPPIV, and the potential to be a novel, efficient and tolerable approach for the diabetes.